中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Envafolimab, The World’s First Subcutaneously Injected PD-L1 Antibody Approved by NMPA! Simcere Partners with Alphamab Oncology and 3DMed to Innovate Immunotherapy

On 26 November 2021, Simcere Pharmaceutical Group Limited (stock code: 2096.HK), 3D Medicines (Beijing) Co., Ltd. ("3DMed") and Alphamab Onc...

2021-11-26
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments

On November 17, 2021, Simcere Pharmaceutical Group Limited (2096.HK) announced that the company has reached collaboration agreement with the Shang...

2021-11-20
IND Application for Simcere’s Independently Developed Anti-TNFR2 Antibody Accepted by CDE

On October 8th, Simcere Pharmaceutical Group (2096.HK), announced that the clinical trial application for its independently developed SIM0235 (SIM1811...

2021-10-14
Envafolimab in Combination with Lenvatinib for the Treatment of Endometrial Cancer Granted Implied License for Clinical Trials

On September, 14, Simcere Pharmaceutical Group Limited (2096.HK) announced that the clinical trials application for Envafolimab in combinati...

2021-09-15
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.